Please login to the form below

Not currently logged in
Email:
Password:

New accounts: February

The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period November 2004 to January 2005 inclusive.

The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period November 2004 to January 2005 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets. To submit an entry for New Accounts, email nhobson@pmlive.com.

Client

Product

Therapeutic area

Winning agency

Alliance Pharmaceuticals

Alphaderm

Dermatology

RFA Advertising

Alliance Pharmaceuticals

Aquadrate

Dermatology

RFA Advertising

Alliance Pharmaceuticals

Acnisal

Dermatology

RFA Advertising

Alliance Pharmaceuticals

Occlusal

Dermatology

RFA Advertising

AstraZeneca

Arimidex

Oncology

Brader Perryman

Biogen

Avonex

Multiple sclerosis

Brader Perryman

Eden Biodesign

N/A

Corporate

Affiniti (UK)

Ferring

Gonapeptyl and Norprolac

Fertility

MJL Advertising

Mencap

Corporate

Learning disabilities

MJL Advertising

Merck Sharp & Dohme

Maxalt

Migraine

PAN Advertising

Novartis

Fortekor

CHF

MJL Advertising

Novartis

Prexige

Osteoarthritis

Brader Perryman

Novartis

Exelon

Alzheimer's disease

Brader Perryman

Servier Laboratories

Procoralan

Cardiovascular

PAN Advertising

Solvay

Omacor

Cardiovascular

Life

Takeda

N/A

Corporate

Brader Perryman

Takeda

Actos

Diabetes

Brader Perryman

Takeda

Amias

Hypertension

Brader Perryman

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics